BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1649 related articles for article (PubMed ID: 32833435)

  • 1. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
    Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
    ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
    Verkhivker G
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
    Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
    Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
    Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
    Ali A; Vijayan R
    Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
    Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
    Guo X; Chen Z; Xia Y; Lin W; Li H
    J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
    Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
    PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
    Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
    Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
    Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
    Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
    Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
    Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
    Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.